How Academic Researchers and Policy Experts Use DrugPatentWatch
Books and Research Papers Citing DrugPatentWatch

All Years | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007

2008 — 4 Books and Research Papers Citing DrugPatentWatch

Doerfling, P., Inouye, S., & Poznanski, L. (2008). A United States Market Entry Analysis for a New Medical Device. Simon Fraser University.
A graduate-level analysis examining market entry strategies for a novel medical device in the U.S. The authors leverage DrugPatentWatch data to map U.S. patent landscapes, regulatory timelines, and competitor positioning. With actionable insights into timing and exclusivity, this study offers a strategic framework for firms navigating patent and regulatory barriers.

Felthouse, D. H. (2008). Focus on Lowest Net Cost Drug Reduces Costs for Patients, Plan Sponsors. American Health & Drug Benefits, 1(9), 10–11.
Drawing from Pharmacy Benefit Management (PBM) trends, this article highlights how emphasizing drugs with the lowest net cost—factoring in rebates and discounts—yields savings for both plan sponsors and beneficiaries. DrugPatentWatch is cited to contextualize pricing dynamics around patent expirations and generic market entry. Empirical data from commercial plans illustrate measurable cost reductions.

Calderini, M., & Odasso, M. C. (2008). Intellectual Property Portfolio Securitization: An Evidence-Based Analysis. Innovation Studies Working Paper.
This working paper explores the emerging practice of securitizing patent portfolios, applying it to evaluate the value of pharmaceutical IP. Using DrugPatentWatch for patent valuation and expiry data, the authors analyze risk-return profiles of patent-backed financial instruments and discuss market readiness for such securitized assets.

Hoffman, J. M., & Koesterer, L. J. (2008). ASHP Guidelines on Medication Cost Management Strategies for Hospitals and Health Systems. American Journal of Health-System Pharmacy.
As part of the American Society of Health-System Pharmacists (ASHP) guidelines, this work recommends best practices to manage medication expenditures. DrugPatentWatch data supports their discussion on patent expiration forecasts and generic availability timelines, enabling evidence-based cost-saving policies for formularies and therapeutic substitution practices.

Sign up for DrugPatentWatch Today

Try a free trial See Plans and Pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.